MetaCap

Amylyx Pharmaceuticals (AMLX) vs Organon (OGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Organon (OGN) has outperformed Amylyx Pharmaceuticals (AMLX) over the past year, gaining 92.9% versus a gain of 77.4%. Organon is the larger company by market cap ($3.65 billion vs $3.35 billion), about 1.1 times the size. Organon pays a dividend yielding 0.58%, while Amylyx Pharmaceuticals does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMLX+77.37%OGN+92.92%
+180%+74%-32%
Nov 21, 20251 yearNov 20, 2026
AMLX+44.00%OGN-57.14%
+137%+18%-102%
Jan 3, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMLX versus OGN key metrics
MetricAMLXOGN
Share price$26.02$13.89
Market cap$3.35B$3.65B
1-day change-0.69%-0.14%
YTD return+115.40%+93.72%
1-year return+77.37%+92.92%
5-year return—-55.38%
P/E ratio (TTM)—17.81
Forward P/E—3.81
EPS (TTM)$-1.43$0.78
Dividend yield0.00%0.58%
Annual dividend$0.00$0.08
Revenue (latest FY)$0$6.22B
Revenue growth (YoY)-100.00%-2.92%
Net income (latest FY)$-144.74M$187.00M
Gross margin—53.30%
Net margin—3.01%
52-week high$41.14$13.94
52-week low$10.83$5.69
Distance from 52-week high-36.75%-0.36%
Analyst consensusstrong_buynone
Avg. price target upside+65.26%-25.63%
Average volume1.53M2.74M
Shares outstanding128.56M262.62M
Employees13610,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OGN has outperformed AMLX by 15.5 percentage points over the past year.
  • Organon grew revenue faster in its latest fiscal year (-2.92% vs -100.00%).

About Amylyx Pharmaceuticals

AMLX stock →

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.

Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees

About Organon

OGN stock →

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees

AMLX vs OGN FAQ

Which is bigger, Amylyx Pharmaceuticals or Organon?

Organon (OGN) is larger, with a market capitalization of $3.65B compared with $3.35B for Amylyx Pharmaceuticals (AMLX).

Which stock has performed better over the past year, AMLX or OGN?

OGN returned +92.92% over the past 12 months, compared with +77.37% for AMLX (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Amylyx Pharmaceuticals or Organon?

Organon pays a dividend yielding 0.58%, while Amylyx Pharmaceuticals does not currently pay a regular dividend.

Are Amylyx Pharmaceuticals and Organon in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons